Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Mechanism Behind Insensitivity to Pain Discovered
Disease Discoveries

Mechanism Behind Insensitivity to Pain Discovered

By Anna WilliamsJun 19, 2017
Share
Facebook Twitter Email
Alfred George, Jr., MD, chair and Magerstadt Professor of Pharmacology, was the senior author of the paper published in The Journal of Clinical Investigation.
Alfred George, Jr., MD, chair and Magerstadt Professor of Pharmacology, was the senior author of the paper published in The Journal of Clinical Investigation.

A new Northwestern Medicine study provides an explanation for how mutations in a sodium channel lead to a genetic disorder featuring insensitivity to pain. The findings, published in The Journal of Clinical Investigation, could also have implications for the development of novel anti-pain drugs.

In particular, the research illuminated how gain-of-function mutations in the sodium channel NaV1.9 are capable of turning off pain-sensing neurons completely or, conversely, heightening their sensitivity and causing them to fire even when unprovoked.

“We now understand this paradox of gain-of-function in NaV1.9 causing both loss of pain and gain of pain. This was a very confusing problem in the field, which we now have solved,” said principal investigator Alfred George, Jr., MD, chair and Magerstadt Professor of Pharmacology.

Carlos Vanoye, PhD, research associate professor of Pharmacology, was the co-first author of the study, which was conducted in collaboration with investigators at Yale University School of Medicine.

A U-shaped figure demonstrates the relationship between the action potential triggering point in the neuron and the membrane voltage. A mild gain-of-function mutation shows on the descending limb of the U, lowering the threshold for generating an electrical impulse, and resulting in increased sensitivity to pain. On the opposite side, a more extreme gain-of-function in the sodium channel leads to depolarization and a lack of ability to fire pain signals.
A U-shaped figure demonstrates the relationship between the action potential triggering point in the neuron and the membrane voltage. A mild gain-of-function mutation shows on the descending limb of the U, lowering the threshold for generating an electrical impulse, and resulting in increased sensitivity to pain. On the opposite side, a more extreme gain-of-function in the sodium channel leads to depolarization and a lack of ability to fire pain signals.

NaV1.9 is one of three voltage-gated sodium channels, along with NaV1.7 and NaV1.8, known to be important for pain sensation in the peripheral nervous system. Mutations in the genes encoding these sodium channels have also been tied to a number of genetic pain disorders, ranging from a condition where patients are unable to feel pain entirely to another disorder causing sudden, severe attacks of pain.

As such, there has been significant interest in investigating the genetics behind these pain disorders, which may validate targets for novel pain therapies.

“Mutations had been identified in NaV1.9 in families that had no pain sensation from birth,” explained George, also director of the Center for Pharmacogenomics. “So we started investigating the functional consequences of those mutations and imagined that we might learn how a drug should modify the channel to alleviate pain.”

George and his collaborators have been particularly focused on NaV1.9, as the sodium channel seemed to lend itself to more selective targeting, compared to NaV1.7 and NaV1.8.

But while previous research on NaV1.7 and NaV1.8 had established a clear relationship between gain-of-function in the channel causing severe pain, and loss-of-function leading to insensitivity to pain, the mechanisms behind NaV1.9 were more complex: Gain-of-function mutations in the channel appeared to cause both loss of pain perception and severe attacks of pain.

“This made no sense — clearly, just knowing what the mutation does to the sodium channel wasn’t the whole story,” George said. To investigate the question, his lab teamed up with scientists at Yale to understand the effect of the mutations on actual nerve cells.

The explanation, they discovered, is that there are different degrees of a gain-of-function in the sodium channel: A mild gain-of-function heightens pain sensation, while a more extreme gain-of-function eliminates pain perception.

“A small perturbation in membrane voltage — which is what happens with a minor gain-of-function — will lower the amount of electrical current needed to fire a neuron. So it’s easier to trigger signaling in pain neurons,” George explained. “But a severe gain-of-function in the sodium channel will depolarize (e.g., make less negative) the neuron severely, and get to a state where it can’t fire an impulse.”

The findings, beyond leading to a deeper molecular understanding of the two genetic disorders, could also inform future drug discovery in targeting NaV1.9.

“Drugs could be developed to modulate NaV1.9 activity and then tested for analgesic effects,” Vanoye explained.

Additionally, while the scientists initially believed that understanding how the sodium channel behaved would provide a blueprint for how to build a novel drug to block pain, the study’s findings suggest a need to rethink the strategy.

“A drug that exactly mimics the effect of the natural mutation might be difficult to fine-tune as an analgesic, because of the chance of having a partial effect and thus changing the channel in the way that would actually increase pain,” George said. “The result from this study has really changed how we think about NaV1.9.”

George is also a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Center for Genetic Medicine.

The study was supported by National Institutes of Health grant NS032387; the Northwestern Medicine Catalyst Fund; the Rehabilitation Research and Development Service and Medical Research Service of the Department of Veterans Affairs; and the Erythromelalgia Association.

Genetics Pharmacology Research
Share. Facebook Twitter Email

Related Posts

Genetic Variations Influence Drug Metabolism in Patients of African Descent

Feb 7, 2023

Potential Therapeutic Target for Schizophrenia Identified 

Feb 6, 2023

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Comments are closed.

Latest News

Workshop Teaches Medical Students Diagnosis Skills in Dermatology

Feb 7, 2023

Genetic Variations Influence Drug Metabolism in Patients of African Descent

Feb 7, 2023

Potential Therapeutic Target for Schizophrenia Identified 

Feb 6, 2023

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Grant Provides Imaging Technology to Department of Ophthalmology

Feb 2, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.